The decision to continue, modify, or discontinue semaglutide should be individualized, weighing the cardiovascular and metabolic benefits of the medication against the impact of gastrointestinal side effects on patient well-being and treatment adherence
A: GLP-1 therapy reduces appetite and slows digestion, leading to reduced food intake and weight loss
Make sure the injection site is clean and ready
Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M (2010) Synthetic therapeutic peptides: science and market
J., Cao, H., Liu, J., & Fei, Y
Sildenafil acts on adipocytes, possibly through cGMP-dependent protein kinase I and mechanistic/mammalian target of rapamycin (mTOR) signaling pathways, browning subcutaneous white fat, thus increasing energy expenditure (232)